After Hours Summary: KMPH -32% after receiving a complete response letter from the FDA; RVNC -22% after trial misses primary endpointsAfter Hours Gainers: None of note
After Hours Losers:
Companies trading lower in after hours in reaction to news: KMPH -31.6% (issued a CRL by the FDA regarding its Apadaz NDA), RVNC -22.1% (reports results from its REALISE 1 Phase 3 trial of RT001; did not achieve its co-primary and other endpoints), IMGN -16% (to offer and sell to the initial purchasers $100 million aggregate principal amount of convertible senior notes due 2021), NERV -3.4% (to offer and sell common stock in an underwritten public offering; size undisclosed), ZBH -1.5% (announces ~11.1 mln common share secondary offering by selling shareholders)